Telix Pharmaceuticals Ltd — Capital/Financing Update 2021

Mar 17, 2021

Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401, 55 Flemington Road North Melbourne Victoria, 3051 Australia

==> picture [146 x 81] intentionally omitted <==

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Melbourne (Australia) and Garching (Germany) – 18[th] March 2021 . Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announced today that it has extended its non-exclusive global clinical and commercial supply agreements with Garching-based ITM Isotopen Technologien München AG (‘ITM’) for the supply of highly pure no-carrier-added (n.c.a.) lutetium-177 ([177] Lu), a therapeutic isotope used in Telix’s portfolio of Molecularly Targeted Radiation (MTR) products.

Telix CEO Christian Behrenbruch stated, “ITM is a leading global supplier of high quality medical radioisotopes, and has established significant production capacity for n.c.a. lutetium, a radioisotope that has potentially broad applications in the treatment of human cancers. These agreements with ITM will support both near-term clinical trial activity and commercial-scale activity in the future.”

ITM CEO Steffen Schuster added, “Through these global supply agreements with Telix, we have further expanded our international leadership position as a premier developer and supplier of radioisotopes. Telix shares our vision of leveraging the full potential of nuclear medicine for the benefit of patients and we look forward to continuing our strong global collaboration with them.”

Under the terms of the revised agreements, ITM will supply[177] Lu for use in Telix’s investigational programs in prostate and renal cancer therapy. Subject to approval of Telix’s drug candidates, ITM will also provide[177] Lu for scale-up and commercialisation. The Company notes that Telix NonExecutive Director, Oliver Buck is a member of the Supervisory Board of ITM. In view of this relationship Mr. Buck did not participate in negotiations in relation to these agreements on behalf of either ITM or Telix, or in board meetings at which they were considered.

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation. Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix’s lead product, Illuccix[®] (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA[1] , and has been granted Priority Review status by the Therapeutic Goods Administration (TGA) in Australia.[2] Telix is also progressing marketing authorisation applications for Illuccix[®] in the European Union[3] and Canada.[4] None of Telix’s products has received a marketing authorisation in any jurisdiction.

About ITM AG

ITM, a privately held radiopharmaceutical biotechology company founded in 2004, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and partners through excellence in development, production and global supply. With

1 ASX disclosure 24/11/2020. 2 ASX disclosure 7/12/2020. 3 ASX disclosure 1/05/2020. 4 ASX disclosure 16/12/2020.

Page 1

patient benefit as the driving principle for all it does, ITM is advancing a broad pipeline combining its superior radioisotopes with targeting molecules to create Precision Oncology treatments. ITM is leveraging its leadership and nearly two decades of radioisotope expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.

Telix Corporate Contact

Dr. Christian Behrenbruch Telix Pharmaceuticals Limited Managing Director and CEO Email: Chris.Behrenbruch@Telixpharma.com

Telix Investor Relations

Dr. David N. Cade Telix Pharmaceuticals Limited CBO and Head of Investor Relations Email: David.Cade@Telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

Page 2